CYX Cytomyx Hldgs

RNS Number:7676A
Cytomyx Holdings PLC
31 March 2006

                              Cytomyx Holdings Plc

                    Result of Extraordinary General Meeting



At the extraordinary general meeting of Cytomyx Holdings Plc ("Company") held
today, all of the resolutions proposed were passed and, as a result, the Company
has completed the disposal of its subsidiary Cytomyx Limited.



Following the disposal, the remaining operating business of the Company is
Cytomyx LLC, which is based in Lexington, MA. USA. Cytomyx LLC supplies high
quality human biospecimens and support services to the biotechnology and
pharmaceutical research industries.



Cytomyx LLC maintains a diverse human tissue biorepository containing over
140,000 samples, all with extensive associated clinical data.  Samples are
bar-coded for tracking purposes and are annotated with associated clinical data
in an on-line database.



These clinical samples are used by clients to better understand the linkage
between gene expression and disease.  By understanding the differences between
patients at the genetic level it is hoped that new medicines will be developed
which precisely target disease in groups of patients.  These targeted (or
personalised) medicines are expected to be significantly more effective and
safer than currently used treatment regimes and new drugs such as Herceptin, a
new treatment for breast cancer, and Gleevec for the treatment of Chronic
Myeloid Leukaemia, have already demonstrated the value of this approach.


                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

EGMJBMTTMMMJBFF

Cytomyx (LSE:CYX)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024

Cytomyx (LSE:CYX)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024